Three years after enrolling its first patients, a consortium of researchers examining the growing issue of immune-related adverse events due to immune checkpoint inhibitor cancer therapy released a ...

This Research Topic is Volume II of a series. The previous volume, which has attracted over 21k views can be found here: New Tumor Immune Checkpoints and ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Outcomes of patients treated with dabrafenib and trametinib who developed pyrexia syndrome and severe/complicated pyrexia syndrome. Comparison between extended and standard infusion in patients with ...

The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

Biomarker analyses provided proof of a mechanism during combination therapy.Yap and his colleagues observed increased CD8+ T cell infiltration and activation in tumors, reduced the regulatory T ...

Dozens of drugs can alter the immune system and affect activity of immune checkpoint inhib ...

Study suggests that persistently activated ATF6α is a tumor driver, a potential stratification marker for immunotherapy response, and a therapeutic target for HCC.

A nationwide cohort study in Taiwan found a higher risk of psoriasis in cancer patients treated with immune checkpoint inhibitors compared to other therapies. The study analyzed data from 3,188 ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature Medicine, the novel monoclonal antibody linavonkibart has demonstrated the ...

Researchers conducted a multicenter observational study across three major US academic medical centers with registries of patients with rheumatic immune-related adverse events to assess the ...